Current approaches to therapy of type 2 diabetes mellitus in the era of new data on cardiovascular safety


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review is dedicated to the analysis of the data of large multicenter studies on the relationship between the risk of cardiovascular events, total mortality, and due to poor diabetes control in adult patients with type 2 diabetes mellitus with cardiovascular diseases (CVDs). It is concluded that all drugs with proven safety can be used in patients with type 2 diabetes mellitus in the presence of CVD [16-20]. In order to reduce the number of cardiovascular events and total mortality, however, preference should be given to drugs with proven benefits in terms of cardiovascular prevention. In particular, sodium-glucose transporter type 2 inhibitor with proven advantages, namely empagliflozin, is include to such drugs.

Full Text

Restricted Access

About the authors

M. B Antsiferov

SBHCI “Endocrinologicla Dispensary" of Moscow Healthcare Department

MD, Prof., Chief Physician

G. Schernthaner

Medical University of Vienna

References

  1. Schernthaner G. Diabetes and cardiovascular disease: is intensive glucose control beneficial or deadly? Lessons from aCCORD, aDVaNCE, VaDT, UKPDS, PROactive, and NICE-SUGaR. Wien Med. Wochenschr. 2010;160:8-19.
  2. Gerstein H.C., Miller M.E., Byington R.P, Goff D.C. Jr, Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm R.H. Jr, Probstfield J.L., Simons-Morton D.G., Friedewald W.T. Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358:2545-59.
  3. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560-72.
  4. Duckworth W., Abraira C., Moritz T. Reda D., Emanuele N., Reaven P.D., Zieve F.J., Marks J., Davis S.N., Hayward R., Warren S.R., Goldman S., McCarren M., Vitek M.E., Henderson W.G., Huang G.D.; VADT Investigators. Intensive glucose control and complications in american veterans with type 2 diabetes. N. Engl. J. Med. 2009;360:129-39.
  5. Johnson J.A., Bowker S.L. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta analysis of major trials. Diabetologia. 2011;54:25-31.
  6. Schernthaner G.H., Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention. Scand. J. Clin. Lab. Invest. 2005;240(Suppl):30-40.
  7. Preis S.R., Hwang S.J., Coady S. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009; 119:1728-35.
  8. Carstensen B., Kristensen J.K., Ottosen P., Borch-Johnsen K. The danish national diabetes register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187-96.
  9. Lind M., Garcia-Rodriguez L.A., Booth G.L., Cea-Soriano L., Shah B.R., Ekeroth G., Lipscombe L.L. Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia. 2013;56:2601-608.
  10. Harding J.L., Shaw J.E., Peeters A., Guiver T., Davidson S., Magliano D.J. Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997-2010. Diabetes Care. 2014;37:2579-88.
  11. Emerging Risk Factors Collaboration, Sarwar N., Gao P., Seshasai S.R., Gobin R., Kaptoge S., Di Angelantonio E., Ingelsson E., Lawlor D.A., Selvin E., Stampfer M., Stehouwer C.D., Lewington S., Pennells L., Thompson A., Sattar N., White I.R., Ray K.K., Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010; 375:2215-22.
  12. Tancredi M., Rosengren A., Svensson A.M., Kosiborod M., Pivodic A., Gudbjörnsdottir S., Wedel H., Clements M., Dahlqvist S., Lind M. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 2015;373:1720-32.
  13. Vazquez-Benitez G., Desai J.R., Xu S., Goodrich G.K, Schroeder E.B., Nichols G.A., Segal J., Butler M.G., Karter A.J., Steiner J.F., Newton K.M., Morales L.S., Pathak R.D., Thomas A., Reynolds K., Kirchner H.L., Waitzfelder B., Elston Lafata J., Adibhatla R., Xu Z., O'Connor P.J. Preventable major cardiovascular events associated with uncontrolled glucose, blood pressure, and lipids and active smoking in adults with diabetes with and without cardiovascular disease: a contemporary analysis. Diabetes Care. 2015;38:905-12.
  14. Hirshberg B., Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36(Suppl 2):253-58.
  15. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
  16. Trial Investigators ORIGIN, Gerstein H.C., Bosch J., Dagenais G.R., Diaz R., Jung H., Maggioni A.P., Pogue J., Probstfield J., Ramachandran A., Riddle M.C., Rydén L.E., Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 2012; 367:319-28.
  17. Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., Ohman P., Frederich R., Wiviott S.D., Hoffman E.B., Cavender M.A., Udell J.A., Desai N.R., Mosenzon O., McGuire D.K, Ray K.K., Leiter L.A., Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 2013;369:1317-26.
  18. White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., Perez A.T., Fleck PR., Mehta C.R., Kupfer S., Wilson C., Cushman W.C., Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 2013;369:1327-35.
  19. Green J.B., Bethel M.A., Armstrong P.W., Buse J.B., Engel S.S., Garg J., Josse R., Kaufman K.D., Koglin J., Korn S., Lachin J.M., McGuire D.K., Pencina M.J., Standl E., Stein P.P., Suryawanshi S., Van de Werf F., Peterson E.D., Holman R.R. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2015;373:232-42.
  20. Pfeffer M.A., Claggett B., Diaz R., Dickstein K., Gerstein H.C., Køber L.V., Lawson F.C., Ping L., Wei X., Lewis E.F., Maggioni A.P., McMurray J.J., Probstfield J.L., Riddle M.C., Solomon S.D., Tardif J.C. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 2015:373:2247-57.
  21. Zinman B., Wanner C., Lachin J.M., Fitchett D., Bluhmki E., Hantel S., Mattheus M., Devins T., Johansen O.E., Woerle H.J., Broedl U.C., Inzucchi S.E. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 2015;373:2117-28.
  22. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 2007;49:1772-80.
  23. Wilcox R., Bousser M.G., Betteridge D.J., Schernthaner G., Pirags V., Kupfer S., Dormandy J. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke. 2007;38:865-73.
  24. Dormandy J.A., Betteridge D.J., Schernthaner G., Pirags V., Norgren L. Impact of peripheral arterial disease in patients with diabetes results from PROactive (PROactive 11). Atherosclerosis. 2009;202:272-81.
  25. Schneider C.A., Ferrannini E., Defronzo R., Schernthaner G., Yates J., Erdmann E. Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 2008;19:182-87.
  26. Mazzone T., Meyer P.M., Feinstein S.B., Davidson M.H., Kondos G.T., DAgostino R.B. Sr, Perez A., Provost J.C., Haffner S.M. Effect of pioglitazone compared with glimepiride on carotid intimamedia thickness in type 2 diabetes: a randomized trial. JAMA. 2006;296:2572-81.
  27. Nissen S.E., Nicholls S.J., Wolski K. Nesto R., Kupfer S., Perez A., Jure H., De Larochellière R., Staniloae C.S., Mavromatis K., Saw J., Hu B., Lincoff A.M., Tuzcu E.M. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299:1561-73.
  28. Schernthaner G. Pleiotropic effects of thiazolidinediones on traditional and nontraditional atherosclerotic risk factors. Int. J. Clin. Pract. 2009;63:912-29.
  29. DeFronzo R.A. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270-87.
  30. Schernthaner G., Currie C.J., Schernthaner G.H. Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care. 2013;36(Suppl 2):S155-S161.
  31. Erdmann E., Charbonnel B., Wilcox R.G. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study. Diabetes Care. 2007;30:2773-78.
  32. Lewis J.D., Habel L.A., Quesenberry C.P., Strom B.L., Peng T., Hedderson M.M., Ehrlich S.F., Mamtani R., Bilker W., Vaughn D.J., Nessel L., Van Den Eeden S.K., Ferrara A. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314:265-77.
  33. Levin D., Bell S., Sund R., et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493-504.
  34. Chilton R., Tikkanen I., Cannon C.P., Crowe S., Woerle H.J., Broedl U.C., Johansen O.E. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes. Metab. 2015;17:1180-93.
  35. Wanner C., Lachin J.M., Fitchett D.H., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease. J. Am. Soc. Nephrol. 2015;26(Suppl B1):1133.
  36. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
  37. Schernthaner G., Barnett A.H., Betteridge D.J., Carmena R., Ceriello A., Charbonnel B., Hanefeld M., Lehmann R., Malecki M.T., Nesto R., Pirags V., Scheen A., Seufert J., Sjohölm A., Tsatsoulis A., DeFronzo R. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia. 2010;53:1258-69.
  38. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach, position statement of the american diabetes association (aDa) and the european association for the study of diabetes (EaSD). Diabetologia. 2012;55:1577-96.
  39. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-49.
  40. Schernthaner G., Schernthaner G.H. Metformin -From Devil to Angel. In: Pharmacotherapy of Diabetes: New Developments. In: CE Mogensen, editor. Wien: Springer, 2008. Р 77-86.
  41. Bailey C.J. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther. 2008;22:215-24.
  42. Schernthaner G., Matthews D.R., Charbonnel B., Hanefeld M., Brunetti P. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J. Clin. Endocrinol. Metab. 2004;89:6068-76.
  43. Deacon C.F., Lebovitz H.E. A comparative review of DPP-4 inhibitors and Sulphonylureas. Diabetes Obes Metab. 2015. doi: 10.1111/dom.12610 [Epub ahead of print]
  44. Schernthaner G., Barnett A.H., Patel S., Hehnke U., von Eynatten M., Woerle H.J. Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged i>65 years. Diabetes Obes. Metab. 2014;16: 1078-86.
  45. Groop P.H., Del Prato S., Taskinen M.R., Owens D.R., Gong Y., Crowe S., Patel S., von Eynatten M., Woerle H.J. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment. Diabetes Obes Metab. 2014;16:560-68.
  46. Schernthaner G., Duran-Garcia S., Hanefeld M., Langslet G., Niskanen L., Östgren C.J., Malvolti E., Hardy E. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes. Metab. 2015;17:630-38.
  47. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., Novials A., Rottiers R., Rutten G.E., Shaw K.M. GUIDE study: double-blind comparison of once- daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur. J. Clin. Invest. 2004;34:535-42.
  48. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., Fosbol E.L., Kober L., Norgaard M.L., Madsen M., Hansen P.R., Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur. Heart J. 2011;32:1900-908.
  49. Abdelmoneim A.S., Eurich D.T., Gamble J.M., Johnson J.A., Seubert J.M., Qiu W., Simpson S.H. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case- control study. Diabetes Obes. Metab. 2014;16:22-9.
  50. Simpson S.H., Lee J., Choi S. Vandermeer B., Abdelmoneim A.S., Featherstone T.R. Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol. 2015;3:43-51.
  51. Gross J.L., Kramer C.K., Leitao C.B., Hawkins N., Viana L.V., Schaan B.D., Pinto L.C., Rodrigues T.C., Azevedo M.J. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann. Intern. Med. 2011;154:672-79.
  52. Esposito K., Chiodini P., Bellastella G., Maiorino M.I., Giugliano D. Proportion of patients at HbA1c target. Diabetes Obes. Metab. 2012; 14:228-33.
  53. Buse J.B., Peters A., Russell-Jones D., Furber S., Donsmark M., Han J., MacConell L., Maggs D., Diamant M. Is insulin the most effective injectable antihy- perglycaemic therapy? Diabetes Obes. Metab. 2015;17:145-51.
  54. Schernthaner G., Gross J.L., Rosenstock J., Guarisco M., Fu M., Yee J., Kawaguchi M., Canovatchel W., Meininger G. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36:2508-15.
  55. Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A., Nissen S.E., Pocock S., Poulter N.R., Ravn L.S., Steinberg W.M., Stockner M., Zinman B., Bergenstal R.M., Buse J.B. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2016;375(4):311-22.
  56. -2671 © 2016 Canadian Diabetes Association. http://dx.doi.org/10.1016/j. jcjd.2016.02.006

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies